Search results for "Coste"

showing 10 items of 368 documents

Pavlovian conditioning of corticotropin-releasing factor-induced increase of blood pressure and corticosterone secretion in the rat

1992

Corticotropin-releasing factor (CRF) is clearly involved in the central regulation of the pituitary-adrenal axis and, moreover, of autonomic nervous system functions. Enhanced sympathetic activity with subsequent increases in blood pressure and heart rate and attenuation of the baroreceptor reflex results from the intracerebroventricular (i.c.v.) administration of CRF. Additionally, the peptide has a variety of potent effects on behavioural responses in animals similar to those observed after an experimentally evoked stress. It was therefore of obvious interest to examine whether CRF is a possible mediator of the learning processes associated with physiological stress reaction patterns. Thi…

Malemedicine.medical_specialtySympathetic Nervous SystemBaroreceptorCorticotropin-Releasing HormonePhysiologyConditioning ClassicalPituitary-Adrenal SystemHemodynamicsBlood Pressurechemistry.chemical_compoundStress PhysiologicalCorticosteroneInternal medicineHeart ratemedicineAnimalsEndocrine systemInjections Intraventricularbusiness.industryClassical conditioningRats Inbred StrainsRatsAutonomic nervous systemEndocrinologyBlood pressurechemistryCorticosteronebusinesshormones hormone substitutes and hormone antagonistsActa Physiologica Scandinavica
researchProduct

Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled study

2010

No data exist about the possibility that vertebral fracture in PMR patients could be independent of steroid therapy. For this reason, we aimed to investigate this topic by a case cohort study with a 1-year follow-up for each patient. We selected ten consecutive patients who experienced vertebral fractures (VF-group) during the first month of 1-year follow-up period and without any other significant associated condition. As a control group we studied ten control patients, without vertebral fractures and with a follow-up of 1 year, randomly selected among a larger group of patients affected by polymyalgia rheumatica. The following data were analysed: eritrosedimention rate (ESR), visual analo…

Malemedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.drug_classGiant Cell ArteritisImmunologyOsteoporosisPilot Projectslaw.inventionCohort StudiesPolymyalgia rheumaticaRheumatologyRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedPain Measurementbusiness.industryCase-control studymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheRheumatologySurgerySettore MED/16 - ReumatologiaGiant cell arteritisTreatment OutcomePolymyalgia RheumaticaCase-Control StudiesPolymyalgia rheumatica Vertebral fractures Osteoporosis Controlled clinical trialSpinal FracturesCorticosteroidFemalebusinessFollow-Up StudiesCohort studyRheumatology International
researchProduct

Intralesional corticosteroid injections in the treatment of central giant cell lesions of the jaws: A meta-analytic study

2013

Objective: The aim of this study was to evaluate the response of treatment of central giant cell lesion to intralesional corticosteroid injections. Study Design: Review of articles indexed in PubMed on the topic between the years 1988 and 2011, and development of a descriptive meta-analysis of the results. Results: Sample of 41 patients primarily treated with intralesional corticosteroid injections was obtained, with a male female ratio of 1:0.95, being 23 aggressive and 18 non-aggressive central giant cell lesions. Triamcinolone acetonide and triamcinolone hexacetonide were the drugs used, and 78.0% cases were considered as good result, 14.6% were considered as moderate response and 7.3% w…

Malemedicine.medical_specialtyTriamcinolone acetonidemedicine.drug_classOdontologíaInjections IntralesionalIntralesional corticosteroidLesionAdrenal Cortex HormonesmedicineHumansGiant Cell TumorsGeneral DentistryTriancinolona AcetonidaOral Medicine and Pathologybusiness.industryGiant Cell TumorsMale femaleReview-ArticleCorticosteroides:CIENCIAS MÉDICAS [UNESCO]Jaw NeoplasmsCiencias de la saludResponse to treatmentSurgeryOtorhinolaryngologyGiant cellUNESCO::CIENCIAS MÉDICASCorticosteroidFemaleSurgerymedicine.symptombusinessmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Differences in the composition of inflammatory cell infiltrate in lens-induced uveitis under therapy with allopurinol or steroids.

2001

Purpose The aim of this study was to compare the qualitative changes in the composition of inflammatory cell infiltrate in lens-induced uveitis (LIU) under treatment with allopurinol (Allo), methylprednisolone (Pred) or the two drugs combined (Allo/Pred). Methods Twenty male Wistar rats were sensitized with lens proteins for eight weeks. Intravenous (IV) therapy was started after anterior capsule disruption in one eye of each animal. Five rats were randomly assigned to each of the four groups: controls, Allo (50 mg/kg bw), Pred (7.5 mg/kg bw) and Allo/Pred (50 mg/7.5 mg per kg bw). Eyes were enucleated 24 hours later and fixed in paraformaldehyde/glutaraldehyde. Sections at three levels wer…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAllopurinolAllopurinolMethylprednisoloneGiemsa stainLens proteinUveitis03 medical and health scienceschemistry.chemical_compoundLeukocyte Count0302 clinical medicineInternal medicinemedicineLeukocytesAnimalsRats WistarParaformaldehydeGlucocorticoidsChemotherapybusiness.industryGeneral MedicineFree Radical Scavengersmedicine.diseaseCrystallinsRatsOphthalmologyDisease Models AnimalEndocrinologychemistryMethylprednisoloneInjections Intravenous030221 ophthalmology & optometryCorticosteroidDrug Therapy Combinationbusiness030217 neurology & neurosurgeryUveitismedicine.drugEuropean journal of ophthalmology
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

2015

International audience; Objective. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.Methods. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the …

Malerheumatoid arthritisGastroenterologycorticosteroidsArthritis Rheumatoidchemistry.chemical_compoundPrednisoneAdrenal Cortex HormonesPharmacology (medical)risksystemic glucocorticoid therapytreatmentfactor-alpha inhibitorsMiddle Aged3. Good healthClinical PracticeTreatment Outcome[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsCorticosteroidDrug Therapy CombinationFemaleAnalysis of variancemanagementmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classAntibodies Monoclonal Humanizeddiseases[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemtocilizumabTocilizumabRheumatology[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationInternal medicinemedicineHumansIn patientbiologicsGlucocorticoidsAgedRetrospective Studiesbusiness.industry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationRepeated measures designeular recommendationsmedicine.diseaseEndocrinologychemistryPrednisonebusiness
researchProduct

Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymph…

1996

International audience; Abstract: The objective was to evaluate the expression of the multidrug resistance P-glycoprotein (P-gp) in peripheral blood lymphocytes (PBL) of patients with rheumatoid arthritis (RA). PBL from 68 RA patients and 44 controls were evaluated. RA patients had a mean disease duration of 10.7 yr, with a mean number of past resistances to DMARDs of 0.82, and were treated with NSAIDs (n = 34), DMARDs (n = 25) and prednisolone (n = 40). Fluorescence flow cytometry was used to assess P-gp membrane expression on PBL. In the RA group, the percentage of PBL expressing P-gp was higher in patients treated with prednisolone than in other patients [mean +/- S.D.: 10.7 +/- 15.8% vs…

Malerheumatoid arthritismedicine.drug_classmedicine.medical_treatmentLymphocytePrednisolone[INFO.INFO-IM] Computer Science [cs]/Medical ImagingDrug resistanceArthritis Rheumatoidresistance03 medical and health sciences0302 clinical medicineRheumatologyImmunopathologyMDRmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansPharmacology (medical)ATP Binding Cassette Transporter Subfamily B Member 1Lymphocytes030304 developmental biologyAgedAutoimmune disease0303 health sciencesChemotherapytreatmentglucocorticoids[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industryAnti-Inflammatory Agents Non-SteroidaldrugMiddle Agedmedicine.diseaseDrug Resistance Multiple3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisAntirheumatic AgentsImmunologyMultivariate AnalysisPrednisoloneCorticosteroidRegression AnalysisFemalebusinessmedicine.drug
researchProduct

Non chiamatele pulci di mare, sono Anfipodi!

2022

Mare Anfipodi CosteSettore BIO/05 - Zoologia
researchProduct

Hyaluronic Acid-Based Micelles as Ocular Platform to Modulate the Loading, Release, and Corneal Permeation of Corticosteroids

2017

The aim of this work is to prepare hyaluronic acid-based micelles as a platform to load corticosteroid drugs and to improve their corneal permeation after administration on the ocular surface. Three amphiphilic derivatives of hyaluronic acid (HA) are synthesized using different amounts of hexadecylamine (C16 -NH2 ). HAC16 a, HAC16 b, and HAC16 c derivatives are able to form micelles by the cosolvent evaporation method and to entrap corticosteroids (dexamethasone, triamcinolone, triamcinolone acetonide). HAC16 a and HAC16 b micelles show the best results in terms of drug loading and particle size. They are also able to improve drug release compared to free drug solution or suspension. In add…

Materials Chemistry2506 Metals and AlloysTriamcinolone acetonidePolymers and PlasticsAdministration Ophthalmic02 engineering and technologyTriamcinolone01 natural sciencesMicelleDexamethasoneCorneachemistry.chemical_compoundDrug Delivery SystemsAdrenal Cortex HormonesHyaluronic acidMaterials ChemistryCorticosteroidAminesCells CulturedMicellesDrug CarriersChemistryPermeation021001 nanoscience & nanotechnology0210 nano-technologyDrug carriermedicine.drugBiotechnologyTranscorneal enhancerHyaluronic acidBioengineering010402 general chemistryPermeabilityBiomaterialsPolymeric micelleAmphiphilemedicineMucoadhesionAnimalsHumansGlucocorticoidsPolymers and PlasticOcular administrationBiomaterialHydrocarbons0104 chemical sciencesDrug LiberationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoBiophysicsCattleEx vivo
researchProduct

Non-Skeletal Activities of Vitamin D: From Physiology to Brain Pathology.

2019

Vitamin D is a secosteroid hormone regulating the expression of almost 900 genes, and it is involved in the regulation of calcium and phosphate metabolism, immune response, and brain development. Low blood vitamin D levels have been reported in patients affected by various diseases. Despite a large amount of literature data, there is uncertainty surrounding the role of vitamin D as a serum biomarker in Alzheimer’s disease (AD) and Parkinson’s disease (PD). Indeed, the lack of internationally recognized 25(OH)D3 reference measurement procedures and standard materials in the past led to unstandardized serum total 25(OH)D3 results among research and clinical care laboratories. Thus…

Medicine (General)Parkinson's diseasePhysiologyvitamin DDiseaseReviewSecosteroidbrain functionchemistry.chemical_compound25(OH)D3R5-920Immune systemAlzheimer DiseaseVitamin D and neurologyMedicineHumansSecosteroidsBrain functionbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseaseVitamin D Deficiencyimmune system25(OH)D<sub>3</sub>chemistryParkinson’s diseaseBiomarker (medicine)businessAlzheimer’s diseaseBiomarkersHormoneMedicina (Kaunas, Lithuania)
researchProduct